ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs, Inc.

Nebula Genomics

ProPhase Diagnostics

ProPhase Labs, Inc. is a growth oriented and diversified diagnostics, genomics and biotech company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. The Company also continues to operate a state-of-the-art contract manufacturing subsidiary and the TK Supplements line of dietary supplements, distributed in food, drug and mass stores throughout the country.

Metric
Company Name	ProPhase Labs, Inc.
Symbol	PRPH
MSH ID	COM:PROPHASELABS
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	US
Stage
Employee Count	113
Website	prophaselabs.com
LinkedIn	prophase-labs
Founders

Metric
Market Cap	66.20M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	45.24M
Revenue (LTM)
Revenue (NTM)
Gross Profit	16.24M
EBITDA	-14.90M
Operating Income	-21.61M
Net Income	-16.78M
EPS	-0.98
Diluted EPS	-0.98
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.37
Operating Profit Margin	-0.48
EBITDA Margin	-0.33
Net Profit Margin	-0.37
Return on Equity	-0.30
Return on Assets	-0.18
Return on Capital Employed	-0.30

COM:PROPHASELABS

ProPhase Labs

Last Close

0.78

22/11 21:00

Market Cap

66.20M

Beta: -

Volume Today

199.40K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.32
P/B Ratio	1.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.54
EV Multiple	-0.64

Metric
Days Sales Outstanding	224.92
Days Payables Outstanding	62.11
Days Inventory Outstanding	71.98
Operating Cycle	740.91
Cash Conversion Cycle	487.25
Asset Turnover	0.49

Metric
Operating Cash Flow	-11.15M
Free Cash Flow	-14.31M
Cash Flow to Debt	-0.66
Operating Cash Flow/Sales	-0.25
Free Cash Flow Yield	-0.15

Metric
Cash & Equivalents	2.15M
Accounts Receivable	-68K
Inventory	3.84M
Goodwill	5.23M
Debt to Capitalization	0.30
Debt to Assets	0.21
Current Ratio	3.04
Quick Ratio	1.99

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06
R&D to Revenue	0.03
SG&A to Revenue	0.69